Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iceutica IncfiledCriticalIceutica Inc
Priority claimed from PCT/US2014/030642external-prioritypatent/WO2014145813A1/en
Publication of MA38521A1publicationCriticalpatent/MA38521A1/en
Publication of MA38521B1publicationCriticalpatent/MA38521B1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La présente invention concerne des compositions pharmaceutiques, notamment des formes de dosage unitaire, comprenant de l'acétate d'abiratérone sous forme de particules fines avec ou sans antioxydant et/ou agent séquestrant, de même que des procédés de production et des méthodes d'utilisation de ces compositions.The present invention relates to pharmaceutical compositions, especially unit dosage forms, comprising abiraterone acetate in the form of fine particles with or without an antioxidant and / or sequestering agent, as well as production methods and methods of use of these compositions.
MA38521A2013-03-152014-03-17
Abiraterone acetate formulation used in the treatment of castration-resistant prostate cancer
MA38521B1
(en)
? compound, pharmaceutical composition, methods to prevent or treat a disease or condition, organ damage, hepatotoxicity and fatty liver, and, use of a compound?
Estra-1,3,5 (10), 16-tetraeno-3-substituted derivatives, pharmaceutical preparations that comprise them and their use in the preparation of medicaments for treating endometriosis.